Karyopharm Therapeutics Inc. Long-Term Debt, Maturity, Year One
Karyopharm Therapeutics Inc. (KPTI) had Long-Term Debt, Maturity, Year One of $5.17 million as of 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2022-03-01
- 2021-12-31: Long-Term Debt, Maturity, Year One $5.17M.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2021-12-31 | $5.17M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |